Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer (Q33584322)

28 July 2017

title

Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer (English)

1 reference

28 July 2017

1 reference

Katrina Bauer

1

1 reference

28 July 2017

Carol Parise

series ordinal

2

1 reference

28 July 2017

Vincent Caggiano

series ordinal

3

1 reference

28 July 2017

language of work or name

English

0 references

publication date

21 May 2010

1 reference

28 July 2017

1 reference

28 July 2017

volume

10

1 reference

28 July 2017

page(s)

228

1 reference

Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886044

Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886044

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886044

Ki-67 expression gives additional prognostic information on St. Gallen 2007 and Adjuvant! Online risk categories in early breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886044

Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886044

The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886044

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886044

Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886044

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886044

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886044

A combination of HER-2 status and the St. Gallen classification provides useful information on prognosis in lymph node-negative breast carcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886044

Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886044

A gene-expression signature as a predictor of survival in breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886044

Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.

21 June 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2407-10-228

The statistical comparison of relative survival rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2407-10-228

Validation of the 2001 St Gallen risk categories for node-negative breast cancer using a database from the Spanish Breast Cancer Research Group (GEICAM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2407-10-228

Evaluation of the prognostic value of 2005 St Gallen risk categories for operated breast cancers in Hong Kong

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2407-10-228

Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer--comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2407-10-228

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2407-10-228

Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist?

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2407-10-228

Potential for false-positive staining with a rabbit monoclonal antibody to progesterone receptor (SP2): findings of the UK National External Quality Assessment Scheme for Immunocytochemistry and FISH highlight the need for correct validation of anti

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2407-10-228

Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2407-10-228

Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2407-10-228

Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1471-2407-10-228

Which tools can I use in daily clinical practice to improve tailoring of treatment for breast cancer? The 2007 St Gallen guidelines and/or Adjuvant! Online

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886044

A risk index for early node-negative breast cancer

31 October 2018

1 reference

12 December 2020

Validation and problems of St-Gallen recommendations of adjuvant therapy for node-negative invasive breast cancer in Japanese patients

1 reference

12 December 2020

Use of the St Gallen classification for patients with node-negative breast cancer may lead to overuse of adjuvant chemotherapy

1 reference

12 December 2020

Meeting Highlights: Adjuvant Therapy for Breast Cancer

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2407-10-228

1 reference

Dimensions Publication ID

28 July 2017

0 references

1 reference

28 July 2017

1 reference